Non-Aqueous Suspensions of Antibodies are Much Less Viscous Than Equally Concentrated Aqueous Solutions

被引:27
作者
Srinivasan, Charudharshini [1 ]
Weight, Alisha K. [1 ]
Bussemer, Till [2 ]
Klibanov, Alexander M. [1 ,3 ]
机构
[1] MIT, Dept Chem, Cambridge, MA 02139 USA
[2] Formulat Dev Sanofi Aventis Deutschland GmbH, Ctr Biol, D-65926 Frankfurt, Germany
[3] MIT, Dept Biol Engn, Cambridge, MA 02139 USA
关键词
amorphous; formulation; proteins; suspension; viscosity; MONOCLONAL-ANTIBODIES; SUBCUTANEOUS DELIVERY; HYDROPHOBIC SALTS; PROTEIN SOLUTIONS; VISCOSITY; FORMULATIONS; CHALLENGES;
D O I
10.1007/s11095-013-1017-4
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
The aim of this study was to markedly lower the viscosities of highly concentrated protein, in particular antibody, formulations. An effective approach elaborated herein for gamma-globulin and a monoclonal antibody is to replace aqueous solutions with equimolar suspensions in neat organic solvents. Viscosities of aqueous solutions and non-aqueous suspensions of the model protein bovine gamma-globulin and a murine monoclonal antibody were examined under a variety of experimental conditions. In addition, protein particle sizes were measured using dynamic light scattering and light microscopy. Concentrated suspensions of amorphous gamma-globulin powders (up to 300 mg/mL, composed of multi-micron-sized particles) in absolute ethanol and a number of other organic solvents were found to have viscosities up to 38 times lower than the corresponding aqueous solutions. Monoclonal antibody follows the same general trend. Additionally, the higher the protein concentration and lower the temperature, the greater the viscosity benefit of a suspension over a solution. The viscosities of concentrated gamma-globulin and monoclonal antibody suspensions in organic solvents are drastically reduced compared to the corresponding aqueous solutions; the magnitude of this reduction depends on the solvent, particularly its hydrogen-bonding properties.
引用
收藏
页码:1749 / 1757
页数:9
相关论文
共 25 条
[1]   Phase behavior of an intact monoclonal antibody [J].
Ahamed, Tangir ;
Esteban, Beatriz N. A. ;
Ottens, Marcel ;
van Dedem, Gijs W. K. ;
van der Wielen, Luuk A. M. ;
Bisschops, Marc A. T. ;
Lee, Albert ;
Pham, Christine ;
Thommes, Jorg .
BIOPHYSICAL JOURNAL, 2007, 93 (02) :610-619
[2]  
Basu SK, 2004, EXPERT OPIN BIOL TH, V4, P301, DOI 10.1517/eobt.4.3.301.27331
[3]   Strategies and challenges for the next generation of therapeutic antibodies [J].
Beck, Alain ;
Wurch, Thierry ;
Bailly, Christian ;
Corvaia, Nathalie .
NATURE REVIEWS IMMUNOLOGY, 2010, 10 (05) :345-352
[4]   Investigating high-concentration monoclonal antibody powder suspension in nonaqueous suspension vehicles for subcutaneous injection [J].
Bowen, Mayumi ;
Armstrong, Nick ;
Maa, Yuh-Fun .
JOURNAL OF PHARMACEUTICAL SCIENCES, 2012, 101 (12) :4433-4443
[5]  
DAI W, 2012, Patent No. 0076800
[6]   Hydrophobic Salts Markedly Diminish Viscosity of Concentrated Protein Solutions [J].
Du, Wei ;
Klibanov, Alexander M. .
BIOTECHNOLOGY AND BIOENGINEERING, 2011, 108 (03) :632-636
[7]  
ENGLARD S, 1990, METHOD ENZYMOL, V182, P285
[8]  
FDA U, 2012, IN INGR SEARCH APPR
[9]   Sustained elevated serum somatotropin concentrations in Holstein steers following subcutaneous delivery of a growth hormone releasing factor analog dispersed in water, oil or microspheres [J].
Foster, TP ;
Moseley, WM ;
Caputo, JF ;
Alaniz, GR ;
Leatherman, MW ;
Yu, X ;
Claflin, WH ;
Reeves, DR ;
Cleary, DL ;
Zantello, MR ;
Krabill, LF ;
Wiest, JR .
JOURNAL OF CONTROLLED RELEASE, 1997, 47 (01) :91-99
[10]   Protein drug stability: A formulation challenge [J].
Frokjaer, S ;
Otzen, DE .
NATURE REVIEWS DRUG DISCOVERY, 2005, 4 (04) :298-306